MEDLAB ANNOUNCES FAVOURABLE INTERIM READOUT OF NANABIS™ REAL-WORLD EVIDENCE (RWE) MEDCARE STUDY N=1,172 Australian pain patientsDatapoints collected from commencing NanaBis™ (baseline) up to month 1255% improvement in pain relief75% of patients reduced their opioid use31% Improvements in Quality...

DEPRESSION PATENT FOR OROTATE APPROVED & GRANTED BY US PATENT OFFICE SYDNEY, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Medlab Clinical LTD (ASX:MDC) is pleased to announce the Orotate patent, specifically to addressing depression in United States of America has been granted....

US Patent Office issues Notice of Allowance status for NRGBiotic™ for treating, preventing, or Ameliorating depression or a Depressive disorder. SYDNEY, July 27, 2021 (GLOBE NEWSWIRE) -- Medlab Clinical Ltd (ASX.MDC), an Australian biotech using delivery platforms to enhance medicines is very pleased to announce the United States Patent...